Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 5
1973 4
1975 3
1976 1
1977 4
1978 3
1979 3
1980 1
1981 4
1982 1
1983 3
1984 2
1985 5
1986 3
1987 6
1988 5
1989 3
1990 7
1991 5
1992 6
1993 6
1994 11
1995 7
1996 6
1997 6
1998 7
1999 4
2000 5
2001 4
2002 6
2003 7
2004 3
2005 5
2006 9
2007 7
2008 3
2009 3
2010 6
2011 5
2012 4
2013 9
2014 9
2015 5
2016 2
2017 3
2018 1
2019 1
2020 1
2021 3
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Results by year

Filters applied: . Clear all
Page 1
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
[No authors listed] [No authors listed] Lancet. 1998 Sep 12;352(9131):837-53. Lancet. 1998. PMID: 9742976 Clinical Trial.
METHODS: 3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a mean of two fasting plasma glucose (FPG) concentrations of 6.1-15.0 mmol/L were randomly assigned intensive policy with a sulphonylurea (ch …
METHODS: 3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a …
Cyclocarya paliurus leaves extracts alleviate metabolic phenotypes in Chinese T2DM patients by modulating gut microbiota and metabolites: a clinical randomized controlled trial.
Peng X, Chen S, Zhong L, Li Y, Wu C, Zhong L, Chen W, Yang J, Zeng J, Tang S. Peng X, et al. Front Endocrinol (Lausanne). 2023 May 24;14:1176256. doi: 10.3389/fendo.2023.1176256. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37293505 Free PMC article. Clinical Trial.
RESULTS: At the end of intervention, CP, like Glipizide, significantly improved HbA1c level and other glucose metabolism parameters (fasting plasma glucose (FBG), 2-hour post-meal blood glucose (2hPBG), the area under curve of oral glucose tolerance test glucose (OGTT gluc …
RESULTS: At the end of intervention, CP, like Glipizide, significantly improved HbA1c level and other glucose metabolism parameters ( …
Glipizide: an overview.
Shuman CR. Shuman CR. Am J Med. 1983 Nov 30;75(5B):55-9. doi: 10.1016/0002-9343(83)90254-1. Am J Med. 1983. PMID: 6369968 Clinical Trial.
This is a brief summary of the extensive clinical experience with glipizide in the treatment of noninsulin-dependent diabetes mellitus. ...
This is a brief summary of the extensive clinical experience with glipizide in the treatment of noninsulin-dependent diabetes mellitu …
Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.
Lebovitz HE. Lebovitz HE. Pharmacotherapy. 1985 Mar-Apr;5(2):63-77. doi: 10.1002/j.1875-9114.1985.tb03405.x. Pharmacotherapy. 1985. PMID: 3923454 Review.
Glipizide is a second-generation sulfonylurea in which the substitutions on the arylsulfonylurea nucleus are large, relatively nonpolar groups. ...The most important component of the antidiabetic action of glipizide is its effect in potentiating insulin action. G
Glipizide is a second-generation sulfonylurea in which the substitutions on the arylsulfonylurea nucleus are large, relatively nonpol
Oral antidiabetic agents in pregnancy and lactation: a paradigm shift?
Feig DS, Briggs GG, Koren G. Feig DS, et al. Ann Pharmacother. 2007 Jul;41(7):1174-80. doi: 10.1345/aph.1K045. Epub 2007 May 29. Ann Pharmacother. 2007. PMID: 17535842 Review.
The human information is inadequate to evaluate the risk of glipizide or the thiazolidinediones in pregnancy. In breast milk, 3 studies measured nonsignificant amounts of metformin and one study was unable to detect either glyburide or glipizide. ...Additional trial …
The human information is inadequate to evaluate the risk of glipizide or the thiazolidinediones in pregnancy. In breast milk, 3 studi …
Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2 diabetics.
Groop L, Wåhlin-Boll E, Groop PH, Tötterman KJ, Melander A, Tolppanen EM, Fyhrqvist F. Groop L, et al. Eur J Clin Pharmacol. 1985;28(6):697-704. doi: 10.1007/BF00607919. Eur J Clin Pharmacol. 1985. PMID: 3933984 Clinical Trial.
Insulin sensitivity was increased by glibenclamide but not by glipizide. Neither therapy affected insulin binding to erythrocytes. It appears that both glibenclamide and glipizide improved glucose metabolism by sustained stimulation of insulin secretion, which was m …
Insulin sensitivity was increased by glibenclamide but not by glipizide. Neither therapy affected insulin binding to erythrocytes. It …
Pharmacokinetics and pharmacodynamics of glipizide after once-daily and divided doses.
Kradjan WA, Takeuchi KY, Opheim KE, Wood FC Jr. Kradjan WA, et al. Pharmacotherapy. 1995 Jul-Aug;15(4):465-71. Pharmacotherapy. 1995. PMID: 7479199 Clinical Trial.
STUDY OBJECTIVE: To determine the pharmacokinetics and pharmacodynamics of glipizide given as a single, oral, 20-mg dose, versus three different divided-dose regimens totaling 20 mg each. ...The divided-dose regimens were designed to simulate delayed absorption of the drug …
STUDY OBJECTIVE: To determine the pharmacokinetics and pharmacodynamics of glipizide given as a single, oral, 20-mg dose, versus thre …
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
Niemi M, Backman JT, Neuvonen M, Neuvonen PJ, Kivistö KT. Niemi M, et al. Clin Pharmacol Ther. 2001 Jun;69(6):400-6. doi: 10.1067/mcp.2001.115822. Clin Pharmacol Ther. 2001. PMID: 11406737 Clinical Trial.
On day 6, a single dose of 1.75 mg glyburide (study I) or 2.5 mg glipizide (study II) was administered orally. Plasma glyburide and glipizide and blood glucose concentrations were measured for 12 hours. ...In some patients, the effects of glipizide may also b …
On day 6, a single dose of 1.75 mg glyburide (study I) or 2.5 mg glipizide (study II) was administered orally. Plasma glyburide and …
Effects of pioglitazone and glipizide on platelet function in patients with type 2 diabetes.
Xiao CC, Ren A, Yang J, Ye SD, Xing XN, Li SM, Chen C, Chen RP. Xiao CC, et al. Eur Rev Med Pharmacol Sci. 2015;19(6):963-70. Eur Rev Med Pharmacol Sci. 2015. PMID: 25855920 Free article. Clinical Trial.

RESULTS: There were no significant differences in baseline characteristics between glipizide and pioglitazone groups. After 24 weeks, fasting blood glucose (p < 0.01) and HbA1c (p < 0.01) were higher in pioglitazone group than those in glipizide group. Fasting

RESULTS: There were no significant differences in baseline characteristics between glipizide and pioglitazone groups. After 24 weeks, …
Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency.
Arjona Ferreira JC, Marre M, Barzilai N, Guo H, Golm GT, Sisk CM, Kaufman KD, Goldstein BJ. Arjona Ferreira JC, et al. Diabetes Care. 2013 May;36(5):1067-73. doi: 10.2337/dc12-1365. Epub 2012 Dec 17. Diabetes Care. 2013. PMID: 23248197 Free PMC article. Clinical Trial.
There was a lower incidence of symptomatic hypoglycemia adverse events (AEs) with sitagliptin versus glipizide (6.2 and 17.0%, respectively; P = 0.001) and a decrease in body weight with sitagliptin (-0.6 kg) versus an increase (1.2 kg) with glipizide (difference, - …
There was a lower incidence of symptomatic hypoglycemia adverse events (AEs) with sitagliptin versus glipizide (6.2 and 17.0%, respec …
213 results